doxepin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tricyclic compounds	956	1668-19-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: P-3693A doxepin doxepine doxepin hydrochloride silenor doxepin HCl	A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors. Molecular weight: 279.38 Formula: C19H21NO CLOGP: 4.09 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -3.94 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

P-3693A
doxepin
doxepine
doxepin hydrochloride
silenor
doxepin HCl

A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.

Molecular weight: 279.38
Formula: C19H21NO
CLOGP: 4.09
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -3.94
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
0.10	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	17.90 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	14 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.20 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	15 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 23, 1969	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	628.13	13.12	435	17871	145238	63325478
Toxicity to various agents	408.51	13.12	425	17881	246825	63223891
Respiratory depression	220.79	13.12	98	18208	13617	63457099
Cardio-respiratory arrest	158.07	13.12	134	18172	59825	63410891
Drug abuse	95.43	13.12	111	18195	72407	63398309
Respiratory arrest	86.06	13.12	73	18233	32572	63438144
Depressed level of consciousness	79.96	13.12	94	18212	61984	63408732
Chronic spontaneous urticaria	74.71	13.12	23	18283	1134	63469582
Urticaria	65.07	13.12	146	18160	165656	63305060
Cardiac arrest	62.96	13.12	103	18203	92442	63378274
Suicidal ideation	60.46	13.12	82	18224	62339	63408377
Suicide attempt	52.99	13.12	76	18230	60842	63409874
Sleep-related eating disorder	51.09	13.12	16	18290	835	63469881
Decreased bronchial secretion	45.80	13.12	9	18297	62	63470654
Skin plaque	45.69	13.12	29	18277	8291	63462425
Systemic lupus erythematosus	45.48	13.12	4	18302	208914	63261802
Depression	45.33	13.12	142	18164	196350	63274366
Joint swelling	43.58	13.12	20	18286	327646	63143070
Pruritus	41.66	13.12	210	18096	361243	63109473
Overdose	39.28	13.12	96	18210	114982	63355734
Insomnia	38.60	13.12	143	18163	215109	63255607
Electrocardiogram QRS complex prolonged	38.47	13.12	23	18283	5915	63464801
Glossodynia	37.41	13.12	4	18302	178872	63291844
Infusion related reaction	35.85	13.12	13	18293	245508	63225208
Drug interaction	35.22	13.12	145	18161	228986	63241730
Coma	33.85	13.12	64	18242	64300	63406416
Rheumatoid arthritis	31.46	13.12	17	18289	253802	63216914
Contraindicated product administered	30.97	13.12	12	18294	217636	63253080
Dermatitis atopic	30.35	13.12	24	18282	9700	63461016
Jaundice neonatal	30.18	13.12	11	18295	914	63469802
Maternal exposure during pregnancy	29.91	13.12	13	18293	220049	63250667
Lipohypertrophy	29.74	13.12	10	18296	655	63470061
Inadequate analgesia	28.94	13.12	15	18291	2928	63467788
Synovitis	28.84	13.12	9	18297	186909	63283807
Diverticulum oesophageal	28.61	13.12	7	18299	144	63470572
Paranasal sinus inflammation	28.44	13.12	9	18297	486	63470230
Somnolence	28.17	13.12	114	18192	178571	63292145
Mandibular mass	27.31	13.12	7	18299	175	63470541
Poisoning	26.96	13.12	26	18280	13674	63457042
Therapeutic product effect decreased	26.91	13.12	11	18295	193176	63277540
Bradypnoea	26.30	13.12	15	18291	3535	63467181
Exposure via ingestion	26.25	13.12	14	18292	2895	63467821
Sleep disorder	25.67	13.12	66	18240	81500	63389216
Death	25.56	13.12	190	18116	374191	63096525
Stress	25.03	13.12	58	18248	67109	63403607
Intentional overdose	24.38	13.12	61	18245	74091	63396625
Therapeutic product effect increased	23.87	13.12	10	18296	1205	63469511
Major depression	23.34	13.12	19	18287	7999	63462717
Hepatic enzyme increased	23.02	13.12	15	18291	202313	63268403
Osteosclerosis	22.47	13.12	14	18292	3874	63466842
Migraine	22.26	13.12	73	18233	103273	63367443
Nail avulsion	22.02	13.12	6	18300	191	63470525
Self esteem decreased	21.95	13.12	8	18298	665	63470051
Drug withdrawal syndrome neonatal	21.60	13.12	11	18295	2070	63468646
Acute lung injury	21.40	13.12	10	18296	1561	63469155
Anxiety	21.32	13.12	121	18185	217420	63253296
Blood glucose fluctuation	20.39	13.12	14	18292	4562	63466154
Restlessness	20.30	13.12	33	18273	29420	63441296
Ventricular arrhythmia	20.17	13.12	13	18293	3815	63466901
Hepatic lesion	19.72	13.12	14	18292	4811	63465905
Febrile neutropenia	19.57	13.12	5	18301	118444	63352272
Dyshidrotic eczema	18.70	13.12	7	18299	627	63470089
Psychotic symptom	18.41	13.12	9	18297	1552	63469164
Sinobronchitis	18.15	13.12	5	18301	166	63470550
Choking	18.04	13.12	18	18288	9861	63460855
Somnambulism	17.99	13.12	14	18292	5529	63465187
Breast adenoma	17.86	13.12	4	18302	55	63470661
Product prescribing error	17.50	13.12	29	18277	26260	63444456
Abdominal discomfort	17.42	13.12	42	18264	320843	63149873
Blood test abnormal	17.40	13.12	22	18284	15607	63455109
Wound	17.38	13.12	13	18293	163250	63307466
Defaecation disorder	17.28	13.12	7	18299	774	63469942
Allergic oedema	16.89	13.12	7	18299	821	63469895
Blood pressure systolic increased	16.64	13.12	40	18266	47357	63423359
Seizure	16.60	13.12	79	18227	132555	63338161
Psoriasis	16.59	13.12	59	18247	86898	63383818
Microcephaly	16.03	13.12	7	18299	933	63469783
Quality of life decreased	16.00	13.12	16	18290	8787	63461929
Restless legs syndrome	15.92	13.12	23	18283	18508	63452208
Scratch	15.91	13.12	14	18292	6551	63464165
Pyrexia	15.72	13.12	76	18230	470402	63000314
Osteoporotic fracture	15.61	13.12	11	18295	3735	63466981
Eczema	15.61	13.12	31	18275	32260	63438456
Mastocytosis	15.59	13.12	6	18300	580	63470136
Papule	15.55	13.12	13	18293	5678	63465038
Blood pressure increased	15.12	13.12	89	18217	161973	63308743
Bradycardia	15.12	13.12	51	18255	73176	63397540
Myofascial pain syndrome	15.07	13.12	9	18297	2309	63468407
Junctional ectopic tachycardia	15.00	13.12	4	18302	117	63470599
Iritis	14.83	13.12	10	18296	3165	63467551
Sedation complication	14.67	13.12	19	18287	13803	63456913
Brain oedema	14.27	13.12	19	18287	14176	63456540
Impaired work ability	14.02	13.12	21	18285	17454	63453262
Suspected suicide	13.94	13.12	13	18293	6555	63464161
Anaphylactic reaction	13.61	13.12	46	18260	66054	63404662
Stomatitis	13.57	13.12	12	18294	138713	63332003
Tinnitus	13.52	13.12	31	18275	35597	63435119
Product use issue	13.49	13.12	27	18279	220493	63250223
Treatment failure	13.39	13.12	23	18283	199020	63271696
Hypothermia	13.38	13.12	18	18288	13563	63457153
Arthropathy	13.32	13.12	30	18276	234762	63235954
Angioedema	13.26	13.12	37	18269	47928	63422788
Arrhythmia	13.19	13.12	32	18274	38108	63432608

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	386.14	17.26	258	8140	97910	34850623
Toxicity to various agents	207.46	17.26	247	8151	200115	34748418
Needle fatigue	154.35	17.26	37	8361	844	34947689
Relapsing-remitting multiple sclerosis	147.90	17.26	37	8361	1013	34947520
Gait spastic	146.32	17.26	37	8361	1059	34947474
Drug abuse	136.24	17.26	142	8256	98954	34849579
Hypertonic bladder	126.86	17.26	37	8361	1827	34946706
Monoparesis	118.46	17.26	37	8361	2309	34946224
Muscle spasticity	85.26	17.26	37	8361	5851	34942682
Central nervous system lesion	81.95	17.26	37	8361	6426	34942107
Micturition urgency	81.61	17.26	37	8361	6488	34942045
Nocturia	79.84	17.26	42	8356	10168	34938365
Pollakiuria	75.17	17.26	51	8347	19623	34928910
Memory impairment	68.37	17.26	67	8331	43251	34905282
Movement disorder	64.81	17.26	39	8359	12209	34936324
Multiple sclerosis relapse	59.79	17.26	38	8360	13095	34935438
Erectile dysfunction	59.31	17.26	45	8353	20592	34927941
Ataxia	57.94	17.26	38	8360	13815	34934718
Insomnia	54.56	17.26	93	8305	103814	34844719
Pulmonary oedema	44.59	17.26	56	8342	47473	34901060
Dysarthria	42.62	17.26	47	8351	34735	34913798
Brugada syndrome	41.97	17.26	13	8385	788	34947745
Anxiety	38.37	17.26	78	8320	99350	34849183
Brain oedema	35.06	17.26	28	8370	13793	34934740
Balance disorder	30.57	17.26	43	8355	40611	34907922
Reduced facial expression	30.38	17.26	11	8387	1080	34947453
Soft tissue haemorrhage	29.97	17.26	7	8391	142	34948391
Illness anxiety disorder	28.77	17.26	7	8391	170	34948363
Cardio-respiratory arrest	28.33	17.26	49	8349	55224	34893309
Somatic symptom disorder	27.11	17.26	9	8389	682	34947851
Hydrocholecystis	26.20	17.26	8	8390	462	34948071
Hypoaesthesia	25.84	17.26	50	8348	61394	34887139
Dermatitis atopic	23.16	17.26	15	8383	5332	34943201
Helplessness	23.02	17.26	5	8393	72	34948461
Dissociation	22.64	17.26	10	8388	1648	34946885
Dissociative disorder	22.02	17.26	7	8391	462	34948071
Disease prodromal stage	21.42	17.26	4	8394	25	34948508
Toxic cardiomyopathy	21.30	17.26	6	8392	261	34948272
Pruritus	20.74	17.26	78	8320	141903	34806630
Thrombocytopenia	20.60	17.26	6	8392	156241	34792292
Overdose	20.51	17.26	58	8340	91001	34857532
Drug dependence	20.29	17.26	27	8371	24190	34924343
Pancreatic disorder	18.98	17.26	9	8389	1745	34946788
Depressed mood	18.48	17.26	23	8375	19294	34929239
Acute kidney injury	18.46	17.26	28	8370	304960	34643573
Wrong patient received product	18.17	17.26	10	8388	2644	34945889
Crime	17.74	17.26	4	8394	69	34948464
Measles	17.60	17.26	5	8393	224	34948309
Bradyphrenia	17.27	17.26	12	8386	4786	34943747
Fall	17.27	17.26	95	8303	202790	34745743

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	1005.52	13.79	705	21896	245062	79476725
Toxicity to various agents	590.60	13.79	658	21943	420882	79300905
Drug abuse	207.85	13.79	243	22358	162448	79559339
Cardio-respiratory arrest	180.04	13.79	186	22415	108324	79613463
Respiratory depression	155.12	13.79	97	22504	27533	79694254
Needle fatigue	137.46	13.79	35	22566	867	79720920
Gait spastic	127.64	13.79	35	22566	1162	79720625
Relapsing-remitting multiple sclerosis	119.39	13.79	35	22566	1484	79720303
Hypertonic bladder	98.30	13.79	39	22562	4162	79717625
Respiratory arrest	95.99	13.79	99	22502	57451	79664336
Monoparesis	94.21	13.79	36	22565	3475	79718312
Insomnia	92.18	13.79	210	22391	244960	79476827
Chronic spontaneous urticaria	73.83	13.79	23	22578	1201	79720586
Cardiac arrest	69.78	13.79	152	22449	171944	79549843
Overdose	66.11	13.79	155	22446	184051	79537736
Nocturia	61.97	13.79	42	22559	13639	79708148
Erectile dysfunction	57.04	13.79	41	22560	14623	79707164
Urticaria	56.04	13.79	146	22455	185055	79536732
Micturition urgency	55.35	13.79	38	22563	12603	79709184
Anxiety	54.04	13.79	174	22427	248338	79473449
Ataxia	48.99	13.79	47	22554	24992	79696795
Electrocardiogram QRS complex prolonged	48.46	13.79	33	22568	10800	79710987
Suicide attempt	47.85	13.79	85	22516	82847	79638940
Central nervous system lesion	46.63	13.79	35	22566	13333	79708454
Decreased bronchial secretion	45.70	13.79	9	22592	64	79721723
Depressed level of consciousness	44.54	13.79	90	22511	96562	79625225
Depression	43.72	13.79	148	22453	216642	79505145
Skin plaque	41.69	13.79	30	22571	10715	79711072
Self esteem decreased	40.86	13.79	14	22587	988	79720799
Poisoning	39.48	13.79	42	22559	25230	79696557
Death	39.45	13.79	285	22316	566229	79155558
Dermatitis atopic	38.84	13.79	28	22573	10028	79711759
Pollakiuria	38.28	13.79	50	22551	37267	79684520
Muscle spasticity	37.71	13.79	38	22563	21437	79700350
Suicidal ideation	37.47	13.79	73	22528	76267	79645520
Sleep-related eating disorder	37.20	13.79	12	22589	702	79721085
Febrile neutropenia	36.75	13.79	10	22591	230989	79490798
Memory impairment	35.75	13.79	90	22511	111644	79610143
Pruritus	34.99	13.79	211	22390	394437	79327350
Brugada syndrome	34.31	13.79	13	22588	1225	79720562
Illness anxiety disorder	34.29	13.79	9	22592	252	79721535
Exposure via ingestion	33.73	13.79	20	22581	5154	79716633
Thrombocytopenia	32.98	13.79	17	22584	265242	79456545
Brain oedema	32.61	13.79	38	22563	25225	79696562
Intentional overdose	32.50	13.79	84	22517	105876	79615911
Coma	32.12	13.79	81	22520	100568	79621219
Infusion related reaction	31.34	13.79	13	22588	230224	79491563
Movement disorder	30.28	13.79	38	22563	27221	79694566
Joint swelling	28.45	13.79	24	22577	288622	79433165
Diverticulum oesophageal	28.11	13.79	7	22594	158	79721629
Pyrexia	27.13	13.79	100	22501	678609	79043178
Lipohypertrophy	27.12	13.79	10	22591	874	79720913
Dyshidrotic eczema	26.85	13.79	9	22592	594	79721193
Mandibular mass	26.05	13.79	7	22594	215	79721572
Neutropenia	25.89	13.79	26	22575	287684	79434103
Bradycardia	25.09	13.79	90	22511	135467	79586320
Therapeutic product effect increased	24.73	13.79	11	22590	1560	79720227
Blood glucose fluctuation	24.43	13.79	18	22583	6664	79715123
Obsessive-compulsive personality disorder	24.37	13.79	6	22595	129	79721658
Hydrocholecystis	23.91	13.79	8	22593	525	79721262
Feeling guilty	23.64	13.79	9	22592	859	79720928
Maternal exposure during pregnancy	23.49	13.79	5	22596	136533	79585254
Restlessness	23.47	13.79	45	22556	46447	79675340
Dizziness	23.47	13.79	240	22361	526201	79195586
Multiple sclerosis relapse	23.44	13.79	45	22556	46488	79675299
Product prescribing error	23.39	13.79	44	22557	44769	79677018
Dysarthria	23.24	13.79	56	22545	67566	79654221
Acute kidney injury	23.13	13.79	73	22528	519331	79202456
Scratch	22.92	13.79	19	22582	8344	79713443
Somatic symptom disorder	22.50	13.79	12	22589	2525	79719262
Helplessness	22.48	13.79	7	22594	365	79721422
Rheumatoid arthritis	22.22	13.79	16	22585	208454	79513333
Depressed mood	22.15	13.79	45	22556	48435	79673352
Somnolence	21.93	13.79	129	22472	238852	79482935
Stress	21.28	13.79	60	22541	79552	79642235
Inadequate analgesia	20.46	13.79	14	22587	4615	79717172
Intentional product misuse	20.07	13.79	66	22535	95099	79626688
Pulmonary congestion	19.95	13.79	31	22570	27069	79694718
Disease progression	19.85	13.79	14	22587	184348	79537439
Drug interaction	19.80	13.79	192	22409	414991	79306796
Renal impairment	19.77	13.79	10	22591	157773	79564014
Panic attack	19.67	13.79	29	22572	24187	79697600
Spinal disorder	19.58	13.79	19	22582	10241	79711546
Alanine aminotransferase increased	19.35	13.79	11	22590	162559	79559228
Bradypnoea	19.25	13.79	15	22586	6037	79715750
Suspected suicide	19.09	13.79	19	22582	10557	79711230
Drug intolerance	18.40	13.79	29	22572	264090	79457697
Synovitis	18.22	13.79	10	22591	150724	79571063
Anaemia	18.12	13.79	65	22536	444950	79276837
Breast adenoma	17.93	13.79	4	22597	55	79721732
Toxic cardiomyopathy	17.70	13.79	6	22595	410	79721377
Interstitial lung disease	17.66	13.79	5	22596	112595	79609192
Soft tissue haemorrhage	17.60	13.79	6	22595	417	79721370
Allergic oedema	17.31	13.79	7	22594	784	79721003
Disease prodromal stage	17.30	13.79	4	22597	65	79721722
Mental impairment	17.22	13.79	24	22577	19012	79702775
Dissociative disorder	17.06	13.79	7	22594	814	79720973
Crime	17.03	13.79	4	22597	70	79721717
Contraindicated product administered	16.91	13.79	12	22589	157526	79564261
Libido decreased	16.52	13.79	13	22588	5308	79716479
Major depression	15.96	13.79	16	22585	8964	79712823
Platelet count decreased	15.95	13.79	19	22582	194645	79527142
Hepatic enzyme increased	15.86	13.79	17	22584	182593	79539194
Pulmonary oedema	15.82	13.79	58	22543	88196	79633591
Off label use	15.73	13.79	173	22428	907042	78814745
Somnambulism	15.69	13.79	13	22588	5708	79716079
Hepatic lesion	15.41	13.79	14	22587	6945	79714842
Acute lung injury	15.20	13.79	10	22591	3090	79718697
Dissociation	15.08	13.79	11	22590	4010	79717777
Neutrophil count decreased	15.06	13.79	4	22597	93955	79627832
Stomatitis	14.70	13.79	12	22589	146745	79575042
Papule	14.67	13.79	14	22587	7393	79714394
Feeling abnormal	14.63	13.79	86	22515	159113	79562674
Osteoporotic fracture	14.56	13.79	11	22590	4229	79717558
Therapeutic product effect decreased	14.51	13.79	15	22586	163848	79557939
Arrhythmia	14.29	13.79	44	22557	61228	79660559
Measles	14.03	13.79	5	22596	396	79721391
Psychotic symptom	13.96	13.79	9	22592	2688	79719099

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D04AX01	DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Other antipruritics
ATC	N06AA12	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
CHEBI has role	CHEBI:35469	antidepressants
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006993	Hypnotics and Sedatives
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D000068776	Sleep Aids, Pharmaceutical
FDA EPC	N0000175752	Tricyclic Antidepressant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atopic dermatitis	indication	24079001	DOID:3310
Depressive disorder	indication	35489007
Anxiety	indication	48694002
Lichen simplex chronicus	indication	53891004
Severe major depression with psychotic features	indication	73867007
Bipolar affective disorder, current episode depression	indication	191627008	DOID:3312
Insomnia	indication	193462001
Itching of skin	indication	418363000
Cholestatic pruritus	off-label use	707150004
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Hyperthyroidism	contraindication	34486009	DOID:7998
Conduction disorder of the heart	contraindication	44808001
Hepatic failure	contraindication	59927004
Sleep apnea	contraindication	73430006	DOID:0050847
Chronic idiopathic constipation	contraindication	82934008
Open-angle glaucoma	contraindication	84494001	DOID:1067
Epilepsy	contraindication	84757009	DOID:1826
Prolonged QT interval	contraindication	111975006
Bipolar affective disorder, current episode manic	contraindication	191618007
Sleep automatism	contraindication	247962006
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Syncope	contraindication	271594007
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Breastfeeding (mother)	contraindication	413712001
Myocardial infarction in recovery phase	contraindication	418044006
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.66	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	10238620	May 18, 2027	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	10653662	May 18, 2027	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	9486437	May 18, 2027	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	9861607	May 18, 2027	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	10238620	May 18, 2027	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	10653662	May 18, 2027	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	9486437	May 18, 2027	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	9861607	May 18, 2027	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	10653660	July 20, 2027	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	11110074	July 20, 2027	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	9572814	July 20, 2027	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	10653660	July 20, 2027	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	11110074	July 20, 2027	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	9572814	July 20, 2027	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	7915307	Aug. 24, 2027	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	7915307	Aug. 24, 2027	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	11234954	Jan. 18, 2028	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	11234954	Jan. 18, 2028	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	10548871	April 11, 2028	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	11096920	April 11, 2028	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	10548871	April 11, 2028	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	11096920	April 11, 2028	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	9107898	May 1, 2028	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	9107898	May 1, 2028	TREATMENT OF INSOMNIA
EQ 3MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	8513299	Sept. 7, 2030	TREATMENT OF INSOMNIA
EQ 6MG BASE	SILENOR	CURRAX	N022036	March 17, 2010	RX	TABLET	ORAL	8513299	Sept. 7, 2030	TREATMENT OF INSOMNIA

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
5%	DOXEPIN HYDROCHLORIDE	TEVA PHARMS	A215408	Feb. 17, 2023	RX	CREAM	TOPICAL	Aug. 16, 2023	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Kd	7.53	WOMBAT-PK	CHEMBL
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	9.75	WOMBAT-PK	DRUG LABEL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.30	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.58	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Kd	7.17	WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.54	WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		EC50	7.45	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		EC50	7.20	WOMBAT-PK
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		EC50	7	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.98	CHEMBL
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN				WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.63	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		IC50	7.21	WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.33	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		EC50	6.50	WOMBAT-PK
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		EC50	6.79	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	7.42	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.80	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.28	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.09	WOMBAT-PK
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.13	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		IC50	7	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.37	DRUG MATRIX
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.95	CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.89	WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.74	DRUG MATRIX
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		EC50	6.50	WOMBAT-PK
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.48	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	11	CHEMBL
Serotonin (5-HT) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT 5HT2B_RAT 5HT6R_RAT 5HT7R_RAT 5HT5A_RAT 5HT5B_RAT 5HT3A_RAT 5HT4R_RAT 5HT3B_RAT		IC50	6.70	CHEMBL

External reference:

ID	Source
4019736	VUID
N0000147828	NUI
D00814	KEGG_DRUG
1229-29-4	SECONDARY_CAS_RN
4017851	VANDF
4019736	VANDF
C0013085	UMLSCUI
CHEBI:4710	CHEBI
CHEMBL1628227	ChEMBL_ID
CHEMBL1628234	ChEMBL_ID
DB01142	DRUGBANK_ID
D004316	MESH_DESCRIPTOR_UI
667477	PUBCHEM_CID
1225	IUPHAR_LIGAND_ID
1855	INN_ID
5ASJ6HUZ7D	UNII
203179	RXNORM
172015	MMSL
239355	MMSL
27123	MMSL
278670	MMSL
3183	MMSL
4638	MMSL
d00217	MMSL
001509	NDDF
004607	NDDF
11841005	SNOMEDCT_US
372587005	SNOMEDCT_US
85037008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
doxepin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-9609	CREAM	50 mg	TOPICAL	ANDA	18 sections
Doxepin	HUMAN PRESCRIPTION DRUG LABEL	1	0228-3315	TABLET, FILM COATED	3 mg	ORAL	ANDA	31 sections
Doxepin	HUMAN PRESCRIPTION DRUG LABEL	1	0228-3316	TABLET, FILM COATED	6 mg	ORAL	ANDA	31 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1049	CAPSULE	10 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1049	CAPSULE	10 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3125	CAPSULE	25 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3125	CAPSULE	25 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4250	CAPSULE	50 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4250	CAPSULE	50 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4810	TABLET	3 mg	ORAL	NDA authorized generic	32 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4811	TABLET	6 mg	ORAL	NDA authorized generic	32 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5375	CAPSULE	75 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5375	CAPSULE	75 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5390	TABLET	3 mg	ORAL	ANDA	34 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5391	TABLET	6 mg	ORAL	ANDA	34 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6410	CAPSULE	100 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-6410	CAPSULE	100 mg	ORAL	ANDA	17 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8117	CREAM	50 mg	TOPICAL	NDA authorized generic	18 sections
Zonalon	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8123	CREAM	50 mg	TOPICAL	NDA	19 sections
PRUDOXIN	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8130	CREAM	50 mg	TOPICAL	NDA	18 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4062	CAPSULE	10 mg	ORAL	ANDA	15 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4062	CAPSULE	10 mg	ORAL	ANDA	15 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4063	CAPSULE	25 mg	ORAL	ANDA	15 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4063	CAPSULE	25 mg	ORAL	ANDA	15 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4064	CAPSULE	50 mg	ORAL	ANDA	15 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4064	CAPSULE	50 mg	ORAL	ANDA	15 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4065	CAPSULE	75 mg	ORAL	ANDA	15 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4065	CAPSULE	75 mg	ORAL	ANDA	15 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4066	CAPSULE	100 mg	ORAL	ANDA	15 sections
Doxepin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-4066	CAPSULE	100 mg	ORAL	ANDA	15 sections